June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Triple Therapy efficacy for evaporative dry eye evaluated through the Keratograph 5M.
Author Affiliations & Notes
  • Jesus Enrique Arreola
    Ophthalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Denise Loya-Garcia
    Ophthalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Jose Roberto Arreola-Martinez
    Ophthalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Alberto Castillo
    Ophthalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Julio Cesar Hernandez-Camarena
    Ophthalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Jorge E Valdez
    Ophthalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Footnotes
    Commercial Relationships   Jesus Arreola None; Denise Loya-Garcia None; Jose Arreola-Martinez None; Alberto Castillo None; Julio Hernandez-Camarena None; Jorge Valdez None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1568 – A0293. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jesus Enrique Arreola, Denise Loya-Garcia, Jose Roberto Arreola-Martinez, Alberto Castillo, Julio Cesar Hernandez-Camarena, Jorge E Valdez; Triple Therapy efficacy for evaporative dry eye evaluated through the Keratograph 5M.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1568 – A0293.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Describe and analyze the effectiveness of triple palpebral therapy in signs and symptoms of evaporative dry eye using dynamic-keratograph parameters.

Methods : Retrospective study of patients with evaporative dry eye disease referred to palpebral therapy sessions from January 2019 to November 2021. Such therapy consisted of 3 sessions once a week during which patients underwent debridement- scaling of the lid margin, followed by moist-heat therapy with Blephasteam® for 10 minutes and meibomian gland manual expression (“Triple therapy”). Ocular Surface Disease Index (OSDI) questionnaire, noninvasive tear break-up time (NITBUT), recorded as the time to first rupture (NITBUTf) and the average time for rupture (NITBUTav), ocular redness, tear meniscus height (TMH) and meibography score were measured before and after the therapy using the OCULUS Keratograph® 5M. Paired t-test and chi-square analysis were used, and the level of statistical significance was taken as p<0.05.

Results : A total of 280 eyes (140 patients) were included, 71% were female. The mean age was 52.32±17.79 years. Meibomian gland abnormalities (grade 2-3) were found in 59.64% of cases, being the lower eyelid the most affected (71.43%). Pre-treatment TMH (millimeters), NITBUTf (seconds), NITBUTav (seconds), ocular redness and OSDI score were 0.22±0.16, 4.48±2.61, 7.03±3.51, 1.56±0.59 and 33.38±24.69, respectively. Post-treatment statistically significant improvement was found in TMH, NITBUTf, NITBUTav, ocular redness, and OSDI score with 0.34±0.20, 8.32±4.51, 11.08±4.77, 1.07±0.47, and 13.60±14.66, respectively (p<.001). Meibography scores had a non-significant statistical change (p=.35). Conjunctival chalasis was only found in 3.93% of cases. Ocular surface diseases other than primary evaporative dry eye disease were present in 10.7% of the eyes. No adverse effects were observed.

Conclusions : Triple therapy showed a significant improvement in evaporative dry eye signs and symptoms after the three-week sessions and appears to be an effective option for these patients. Studies to evaluate the long-term effect of the treatment may be necessary.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×